MOTION: A randomized, phase 3, placebo-controlled, double-blind study of vimseltinib (DCC-3014) for the treatment of tenosynovial giant cell tumor Meeting Abstract
| Authors: | Tap, W. D.; Wagner, A. J.; Sharma, M. G.; Vallee, M.; Michenzie, M. F.; Sherman, M. L.; Ruiz-Soto, R.; Stacchiotti, S.; van de Sande, M. A. J.; Gelderblom, H. |
| Abstract Title: | MOTION: A randomized, phase 3, placebo-controlled, double-blind study of vimseltinib (DCC-3014) for the treatment of tenosynovial giant cell tumor |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680304798 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.TPS11590 |
| Notes: | Meeting Abstract: TPS11590 -- Meeting also held virtually -- Source: Wos |
